Park Avenue Securities LLC Invests $445,000 in TransMedics Group, Inc. $TMDX

Key Points

• Park Avenue Securities LLC has invested approximately $445,000 in TransMedics Group, acquiring 3,322 shares of the company during the second quarter.
• TransMedics Group reported a 37.7% year-over-year increase in revenue, with quarterly earnings of $0.92 per share, surpassing analysts' expectations.
• Research analysts have given TransMedics Group an average rating of "Moderate Buy", with a consensus price target of $125.40 for its stock.

Park Avenue Securities LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,322 shares of the company's stock, valued at approximately $445,000.

Other large investors have also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC lifted its holdings in TransMedics Group by 52.6% in the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock valued at $403,000 after acquiring an additional 2,065 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in TransMedics Group by 2.8% in the first quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock valued at $13,350,000 after acquiring an additional 5,480 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in TransMedics Group in the first quarter valued at approximately $291,000. New York State Teachers Retirement System lifted its holdings in TransMedics Group by 183.2% in the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock valued at $1,477,000 after acquiring an additional 14,200 shares during the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new position in TransMedics Group in the first quarter valued at approximately $740,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Down 1.1%

TransMedics Group stock opened at $112.64 on Tuesday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $159.57. The stock's fifty day simple moving average is $116.44 and its 200-day simple moving average is $109.61. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a market capitalization of $3.84 billion, a P/E ratio of 58.36 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the prior year, the company earned $0.35 earnings per share. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on TMDX shares. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer upped their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Evercore ISI assumed coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 target price on the stock. Morgan Stanley boosted their target price on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Finally, Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $125.40.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.